



Tayte, age 4, diagnosed with
type 1 diabetes in 2012

One Voice

Contents

Our Mission	1
What is Type 1 Diabetes?	2
Who is JDRF?	3
Message from the Chairman	4
Message from the Chief Executive Officer	5
Type 1 Diabetes Research	6
The Diabetes Research Innovation Award 2012	7
Curing Type 1 Diabetes	8 - 9
Treating Type 1 Diabetes	10 - 11
Preventing Type 1 Diabetes	12 - 13
FY 2012-13 Australian Research Funded by JDRF	14 - 15
The Clinical Research Network	16
A Young Advocate	17
Community Voices	18
Community Voices in Canberra	19
Connecting Communities	20 - 21
Funding a Cure	22 - 23
A Common Cause	24
Craig Alexander and the Kilanda Fireworks	25
Recognising Achievements of Health Care Professionals	26
Recognising Achievements of Passionate Volunteers	26
Greg Donovan and The Big Red Run	27
Our Corporate Supporters	28 - 29
Our Industry Partners	30 - 31
Recognising Generous Contributors	32 - 33
Corporate Governance	34 - 35
Board of Directors	36 - 38
Advisory Board	39
Senior Managers	40
Advisory Panels	41
JDRF Australia Financial Report	42 - 44
Contact JDRF	45

Our Mission

To find a cure for type 1 diabetes and its complications through the support of research.

Our Progress

\$5.8m
invested
in Australian
research

76 insulin pumps
distributed

2591
support
resources
distributed

37 Australian research
projects supported

\$9.3m
raised
through
fundraising
activities

What is type 1 diabetes?

Type 1 diabetes is the disease that unites 122,300 Australians and their friends and families.

Type 1 diabetes is a lifelong autoimmune disease that destroys the body's ability to produce insulin, a hormone that is essential for life. People can be diagnosed with the disease at any age, though diagnosis is most common in children.

People with type 1 diabetes need multiple insulin injections or a continuous infusion from an insulin pump every single day. The strict daily regime of blood glucose management can be a heavy burden, impacting quality of life through the constant fear of hypoglycaemia and risk of complications.

The causes of type 1 diabetes are not fully understood, though genetic and environmental triggers play a role. There is currently no way to prevent or cure type 1 diabetes.

With the help of the Australian type 1 diabetes community and its supporters, JDRF is supporting research to cure, treat and prevent type 1 diabetes.

Who is JDRF?


JDRF is the global not-for-profit leader in funding type 1 diabetes research.

We are the organisation with links across the world to the world's leading research institutions. We strategically influence and guide the best research into type 1 diabetes around the world, and we have supported nearly every major advance in type 1 diabetes research in the past 40 years.

We are the organisation that gives a voice to 122,300 Australians with type 1 diabetes. Our type 1 diabetes advocates meet with influential members of Parliament to speak on behalf of the Australian type 1 diabetes community. They advocate for the support of type 1 diabetes research and improvements to the health system for all people with type 1 diabetes.

We are the organisation that supports individuals and families who are learning to live with type 1 diabetes. Through information, resources and support, we provide the help people need at different stages of their life with type 1 diabetes.

We are the organisation that connects and unites the Australian type 1 diabetes community through events, forums, groups and activities. We help to build a strong community with a common purpose.



While JDRF is working on finding a cure for type 1 diabetes and its complications, we also work to deliver improved quality of life and community connections to those living with the disease.

We believe in:

INTEGRITY
TEAMWORK
PASSION
EXCELLENCE
RESPECT
EMPATHY
COMMITMENT
CREATIVITY

Message from the Chairman

JDRF leadership continues to increase the volume and quality of Australian type 1 diabetes research progress.

I congratulate all of the volunteers, donors, and staff on a year of substantial

achievements for JDRF in Australia, as you will read

in this report. These achievements were recognised with JDRF being presented the 2013 Australian Charity Award for Outstanding Achievement.

In particular, our advocacy activities over the past financial year have positively impacted the future of Australian clinical trials with the commitment of \$35m over the next five years from the Coalition for the JDRF's Type 1 Diabetes Clinical Research Network (CRN).

This commitment validates the strategic move to closer interaction by JDRF with the research community and with Governments, in addition to our core fundraising activities, commenced more than five years ago. This continues to reshape JDRF and enable us to have even more positive impact on Australian research. I am incredibly excited about these developments for JDRF, and look forward to seeing what the next five years will bring.



At a Board level, I am pleased to share with you that we have had a number of new directors join the Board in the past 12 months, providing JDRF with access to new skills, networks, and support. This is also an important part of the gradual renewal of the Board, as a number of directors have been on the Board for ten years or more.

As part of this renewal process, I have been on the Board for 20 years and have indicated my desire to expand my JDRF involvement outside the Board, and so will not stand for re-election at the end of this term. It has been an absolute pleasure to work with the wonderful JDRF family of passionate and professional staff and volunteers, and in particular I am grateful to my fellow directors for their support over many years.

I thank the Board of Directors, Advisory Board, Lay and Professional Advisory Panels, as well as State Committees and our many, many volunteers for their dedication to JDRF and commitment to funding, managing and influencing the growth and direction of type 1 diabetes research.

Finally, I thank the scientists and the researchers who dedicate their life's work to JDRF's mission – finding a cure for type 1 diabetes and its complications. You give us all hope for a future free of this disease.

A handwritten signature in black ink, which appears to read 'Stephen Higgs'.

Stephen Higgs
Chairman

Message from the Chief Executive Officer

In FY 2012-13, JDRF continued to fund the best and most promising Australian research into curing, treating and preventing type 1 diabetes.



Research Investment

We invested \$5.8m directly in Australian research and support programs, including direct funding for Australian research projects, management of Government-funded research and support initiatives, fellowships, conference grants, postgraduate scholarships, and travel grants for young scientists, and a range of other support programs.

In addition to support provided by JDRF for Australian research, further funding for Australian research was also provided by US-based JDRF International.

We were also very pleased to launch, in partnership with the National Health and Medical Research Council, the next round of jointly funded Centre of Excellence grants for type 1 diabetes. This program will commit \$12.5m over five years to Australian research.

Financial Performance

We raised funds from a variety of sources to support our ability to invest in Australian type 1 diabetes research. In FY 2012-13, we grew our capacity to fundraise through Team Cure Diabetes and our Major Giving and Bequest programs, and grew total fundraising overall.

In the year ended 30 June 2013, accounts show a surplus from continuing operations of \$267k, positioning us strongly for the future.

Total Revenue

FY 2012-13 \$11.1m

FY 2011-12 \$10.8m

Total increase 4%

Revenue from fundraising activities

FY 2012-13 \$9.3m

FY 2011-12 \$8.5m

Revenue from government grants

FY 2012-13 \$1.4m FY 2011-12 \$1.6m

Community and Government Engagement

A highlight for FY 2012-13 was the *Promise to Remember Me* advocacy campaign, which culminated in the *Kids in the House* event in Parliament House Canberra. JDRF's advocates activities helped to produce a commitment from the Coalition of \$35m for the expansion of the Australian Type 1 Diabetes Clinical Research Network (CRN) – the largest ever single commitment to type 1 diabetes in Australia.

JDRF's investment into research is not possible without the strong support of the Australian type 1 diabetes community and their family and friends. JDRF grew its engagement with the type 1 diabetes community, reaching out through the Peer Support Program to 90% of newly diagnosed children and families known to JDRF, who also received a *KIDSAC* or *t1d kit* upon diagnosis.

In these ways and many more, JDRF continues to lead, support, and influence the best type 1 diabetes research in Australia.

Mike Wilson
Chief Executive Officer & Managing Director

Type 1 Diabetes Research

Globally, JDRF has funded more than \$1.7 billion of type 1 diabetes research since 1970, with nearly \$160m invested in Australia since 1985.

Curing type 1 diabetes.

For those who have been diagnosed with type 1 diabetes, we will **cure** the disease by replacing or renewing insulin-producing beta cells and blocking the autoimmune attack in type 1 diabetes.

Treating type 1 diabetes.

For those already living with type 1 diabetes, we will **treat** the disease with more advanced and efficient technologies and therapies that will help to manage blood glucose levels, reduce the risk of complications and improve overall quality of life.

Preventing type 1 diabetes.

For those who are at risk of developing type 1 diabetes, we will **prevent** the disease in current and future generations by creating a vaccine or therapy that will stop or reverse the autoimmune attack that leads to type 1 diabetes.

In FY 2012-13:

- Over \$5.8m invested in Australia
- 37 research grants and projects supported in Australia

The Diabetes Research Innovation Award 2012

Dr Cecile King, Garvan Institute of Medical Research

Dr Cecile King at the Garvan Institute of Medical Research is a talented young investigator who is rapidly establishing herself as a rising star in the field of autoimmune disease, and a fantastic example of how JDRF's early career research funding can result in continued excellence of research results as an advanced researcher.

Since 1998, she has received a number of JDRF grants, fellowships and awards, in recognition of the importance of her work on the IL-21 growth factor in type 1 diabetes. She is a respected authority on this growth factor, and its implications for curing type 1 diabetes.

Her recent work on the prevention of allograft rejection during islet transplantation procedures was awarded the 2012 JDRF and Macquarie Group Foundation Diabetes Research Innovation Award. Published in the journal *Diabetes*, the importance of her findings was illustrated by the fact that the journal chose to highlight these findings with accompanying commentary.

The impact of Dr King's research is clear, as changes to the growth factor IL-21 could be successful in improving the success of human islet transplantation.




Dr Cecile King

Research Fellow, Garvan Institute of Medical Research

Winner of the 2012 JDRF and Macquarie Group Foundation Diabetes Research Innovation Award

Curing type 1 diabetes

- **Australian researchers have published their results on the outcomes of the JDRF Islet Transplantation Program, which was funded by the Department of Health and Ageing and administered by JDRF between 2005 and 2011.** They reported that 82% of the seventeen patients in the program achieved the goal of eliminating severe hypoglycaemia and HbA1c levels of under 7%. 53% of these respondents were insulin-independent for between 7-39 months, and 35% are still insulin-independent. This report demonstrates that investment into islet transplantation procedures led to positive patient outcomes. This strengthens the case for funding of islet transplantation through the health system for people with severe brittle diabetes.
- **JDRF-funded researchers have created a new biomaterial called 'hydrogel' that improves the success of islet transplantation procedures in mice.** The researchers coated donor islet cells with the hydrogel, which formed a protective layer around the islets, and injected the protected cells into a different part of the body than is normally used in transplants. The results showed that the hydrogel and new injection site were successful in allowing the transplanted islets to survive, with the test mice achieving normal blood glucose levels within four weeks of the procedure. In the future, if the hydrogel can be proven to be capable of protecting transplanted human islets from the autoimmune reaction of type 1 diabetes and the immune reaction to the foreign islets, there is great potential for the hydrogel to be adopted for use as a material to improve the efficiency of beta cell replacement therapies.
- **JDRF has brought together scientists from more than 25 top institutions to create the new JDRF Encapsulation Consortium.** Under JDRF's leadership, this multi-site collaboration will help to accelerate next generation encapsulation product research and development. This includes two new partnerships between JDRF and Living Cell Technologies (LCT) and ViaCyte Inc. to develop durable and effective beta cell encapsulation products to restore insulin independence in people with type 1 diabetes.
- **JDRF-funded Australian researchers have clarified the role of granzymes in the development of type 1 diabetes.** Granzymes are molecules produced by killer T-cells of the immune system, which are responsible for the physical destruction of insulin-producing beta cells in type 1 diabetes. The researchers found that the absence of granzymes in non-obese diabetic mice with a predisposition to type 1 diabetes did not prevent the destruction of beta cells, and still led to later development of type 1 diabetes. This discovery has explained that granzymes may not be a factor in the development of type 1 diabetes, which allows future studies to focus on other molecules produced by killer T-cells for development of future immune therapies.



The JDRF-funded nPOD (Network for Pancreatic Organ Donors with Diabetes) initiative is collecting and studying donor pancreases from adults with type 1 diabetes, and adults with antibodies for type 1 diabetes but who haven't yet developed the disease.

Previous studies have suggested that the size and weight of the pancreas in adults with type 1 diabetes is less than in people without diabetes, however it is not known whether this is a result of type 1 diabetes or if it happens before diagnosis.


Results from nPOD studies indicate that the reduction in pancreas weight happens before diagnosis of type 1 diabetes, with no influence from the donors' age, weight, or cause of death.

This suggests that there are unknown factors that can influence the size of the pancreas before the development of type 1 diabetes, and may actually contribute to the development of the disease as well.

These results will inform further studies into the cause of type 1 diabetes, and potentially offer pathways to cure type 1 diabetes.

Average weight of the pancreas in adults with type 1 diabetes is 45% less than the weight of the pancreas in adults without type 1 diabetes.

Average weight of the pancreas in adults who were at risk of type 1 diabetes was 24% less than adults not at risk of type 1 diabetes.



The nPOD initiative demonstrates how JDRF investment into coordinated research programs and networks can produce research results with great potential for new avenues of therapies.

Treating type 1 diabetes

- 🌀 **Australian JDRF-funded researchers have found that blood glucose sensor-augmented insulin pump therapy with automated low glucose insulin suspension has helped to reduce the incidence of severe hypoglycaemia in people with type 1 diabetes.**

The incidence of severe hypoglycaemia was reduced significantly, with no deterioration in HbA1c in the study participants and a reported reduced fear of nocturnal hypoglycaemia. The results of this study and further trials could lead to widespread use of a low glucose suspend feature in insulin pumps, which could significantly reduce the distress and risk associated with hypoglycaemia.

- 🌀 **JDRF-funded Australian researchers have shown that reducing the AGE content in the diet of mice does not prevent or delay the development of kidney disease.**

Levels of advanced glycation end-products (AGEs) are higher in people with type 1 diabetes and are believed to contribute towards development of diabetes-related complications. However, the study found that when the mice don't have the 'receptor' for AGEs (known as RAGE), the development of kidney disease was delayed. This shows that dietary AGEs may play a smaller role in the development of diabetes-related complications than previously thought, and that the interaction between AGEs and RAGE (the AGE-RAGE axis) could be a major target to delay or prevent the development of diabetes-related kidney disease.

- 🌀 **JDRF-funded researchers have found in a pilot study that the amount of fat in a diet may also be important in calculating how much insulin is required by people with type 1 diabetes.** Patients in the study were provided with two types of dinners with the same protein and carbohydrate content, but different fat content. Results showed that the high-fat dinner required more insulin to stabilise blood glucose levels, and caused more instances of hyperglycaemia. Moving forward, studies with a larger study group are required to fully understand how blood glucose levels in people with type 1 diabetes are affected by the fat content of their diets.

- 🌀 **JDRF has launched CONCEPTT, a clinical study that examines the effects of poorly controlled type 1 diabetes during pregnancy on both mother and child.** This study aims to determine whether the use of continuous glucose monitors will help to improve glucose control in women with type 1 diabetes who are pregnant or planning to become pregnant. The results of this study could have wide-ranging benefits for mothers with type 1 diabetes and their babies, and potentially establish new standards of care for treatment of type 1 diabetes during pregnancy.



Next generation Artificial Pancreas systems will recreate the function of a healthy pancreas by supplying insulin and other pancreatic hormones like glucagon, providing more effective diabetes management.

Previous JDRF research studies have shown that the addition of glucagon to insulin treatment in type 1 diabetes can reduce the frequency of hypoglycaemia.

To help produce a next-generation Artificial Pancreas, JDRF has partnered with three companies to develop products that can help to restore hormones other than insulin in people with type 1 diabetes.

1 JDRF has partnered with Tandem Diabetes Care to create a dual-chamber infusion pump for type 1 diabetes management. JDRF will support Tandem in performance-based milestone funding over two years to complete the development, testing and manufacturing of this dual-chamber pump that can simultaneously deliver two injectable hormonal drug therapies.

2 With JDRF's support, Xeris Pharmaceuticals Inc. will further develop its stable, room-temperature, and non-aqueous injectable glucagon to treat hypoglycaemia, with a view to clinical trials within two years of JDRF funding.

3 LATITUDE Pharmaceuticals Inc. plans to take their unique proprietary solvent-free glucagon nanoemulsion to clinical trials in 2014, with the support of JDRF funding.

If these partnerships can help to create a dual-chamber infusion pump that can deliver dissolvable glucagon at the same time as insulin, it could help improve the treatment of type 1 diabetes for people already living with the disease.

Preventing type 1 diabetes


- **JDRF-funded researchers have proven that early exposure to gut bacteria can affect sex hormone levels in non-obese diabetic (NOD) mice, which in turn can determine the development of type 1 diabetes.**

Gut bacteria are an increasing area of interest for researchers, with several studies showing that gut microorganisms play a role in the development of type 1 diabetes. This study found that after transferring bacteria from male mice to female mice, the testosterone levels in the female mice increased, and protected them from developing type 1 diabetes. If these results can translate to a human model, it could lead to the development of therapies using non-disease causing microorganism to prevent the progression of type 1 diabetes in high-risk individuals.

- **JDRF-funded researchers have shown for the first time that a single gene called SIRT1 may be involved in the development of type 1 diabetes and other autoimmune diseases.** The study revealed that a single mutation on the gene SIRT1 was a common factor in a family with a very strong history of autoimmune diseases, including type 1 diabetes. To understand how this mutation led to the development of type 1 diabetes, the researchers studied animal models of the gene and found that removing the gene in mice resulted in a higher likelihood of type 1 diabetes, with higher

levels of beta cell death. This discovery could help to further research not only into understanding what causes type 1 diabetes, but also in the development of new therapies and treatments to maintain the survival of beta cell function for people at risk of developing type 1 diabetes.

- **To prevent the progression of type 1 diabetes, JDRF-funded researchers have tested a genetically engineered DNA vaccine with a gene sequence for insulin.** The aim of this vaccine was to train the immune system to rethink and reverse the autoimmune attack on pancreatic beta cells. Researchers then measured levels of C-peptide, which indicate the level of beta cell function, and number of insulin-specific killer T-cells of the immune system. The promising results of this study showed that the vaccine led to increased C-peptide levels, and decreased insulin-specific killer T-cells. Further clinical trials will determine whether or not the dosage of this vaccine is sufficient to sustain the reversal of the autoimmune attack in people with type 1 diabetes.




Australian JDRF-funded researchers have developed a promising, rapid and cost-effective method to screen for the genetic risk of developing type 1 diabetes.

By narrowing down the genes that need to be screened, these researchers have helped to build a faster and more cost-effective way of determining genetic risk of type 1 diabetes. This discovery can help to improve recruitment activities for large-scale clinical trials that focus on preventing type 1 diabetes in individuals at high risk of developing this disease.

Historically, the tests that screen for the changes in genetic makeup that can increase the risk of developing type 1 diabetes have been time consuming and expensive due to the sheer volume of genes to screen.

For the first time, these researchers have analysed over 19,000 genetic changes in 10,579 subjects from the Type 1 Diabetes Genetics Consortium (which is partially sponsored by JDRF), and found three individual genetic changes that can determine whether an individual is at risk of developing type 1 diabetes.



FY 2012-13 Australian research funded by JDRF

JDRF Grants

Principal Investigator	Institute	State	Project
Australia III: DVDC		NSW, VIC	Australia III – DVDC (Diabetes Vaccine Development Centre)
Australian IV			Australia IV
Dr Krishnamurthy Balasubramanian	St Vincent's Institute of Medical Research	VIC	The role of proinsulin specific T cells after the onset of autoimmunity
Dr Vicki Bonke	Baker IDI Heart and Diabetes Institute	VIC	Synergistic actions of NADPH oxidase and PKC in diabetic nephropathy
Prof Peter Colman	Walter and Eliza Hall Institute of Medical Research	VIC	Type 1 Diabetes TrialNet International Site – Australia/New Zealand
Prof Mark Cooper	Baker IDI Heart and Diabetes Institute	VIC	Set 7: a novel target for diabetic vascular complications
Dr Katie Edwards	Queensland University of Technology (QUT)	QLD	Novel corneal nerve tests in diabetic neuropathy; growth rate and mapping
Prof Nathan Efron	Queensland University of Technology (QUT)	QLD	A longitudinal study of ophthalmic markers of neuropathy in Type 1 diabetes
Prof Assam El-Osta	Baker IDI Heart and Diabetes Institute	VIC	Understanding the mediators of metabolic memory
A/Prof Josephine Forbes	Mater Medical Research Institute Limited	QLD	Novel therapies to slow the onset of type 1 diabetes
Dr Esteban Gurzov	St Vincent's Institute of Medical Research	VIC	The role of PTPN2 & PTPN22 in pancreatic B-cell function and survival
Dr Emma Hamilton-Williams	University of Queensland	QLD	A genetic link between gut microbial flora and type 1 diabetes susceptibility
Dr Daniel Hesselton	Garvan Institute of Medical Research	NSW	A loss-of-function approach for acinar to beta-cell transdifferentiation
Dr Mugdha Joglekar	University of Sydney	NSW	Inhibition of cytotoxic T lymphocyte-mediated beta cell killing
Prof Tim Jones	University of Western Australia	WA	Adolescent diabetes intervention trial: Australia
Prof Tim Jones	University of Western Australia	WA	Low Glucose Suspend Study
Prof Tom Kay	St Vincent's Institute of Medical Research	VIC	Identifying islet factors that stimulate effector capacity in CTLs
Dr Jan Kranich	Garvan Institute of Medical Research	NSW	Gut bacteria, short-chain fatty acids and Gpr43 in type 1 diabetes
Dr Trang Ly	The University of Western Australia	WA	Low Glucose Suspend Study
Dr Eliana Marino	Monash University	VIC	Gut permeability, inflammation and microbiota modulate type 1 diabetes
Dr Stuart Mannering	St Vincent's Institute of Medical Research	VIC	Analysis of human islet-infiltrating T cells in type 1 diabetes
Prof Anthony Purcell	Monash University	VIC	Presentation of post-translationally modified antigenic peptides in type 1 diabetes
Dr Mariyo Sakoda	Baker IDI Heart and Diabetes Institute	VIC	Diabetic nephropathy: role of renin-angiotensin system and memory

JDRF Grants cont.

Principal Investigator	Institute	State	Project
Dr Charmaine Simeonovic	The Australian National University	ACT	Heparan sulphate mimetics for protection of human islet beta cells
Prof Jonathan Sprent	Garvan Institute of Medical Research	NSW	Treg expansion for islet allotransplantation
Dr Sih Min Tan	Baker IDI Heart and Diabetes Institute	VIC	The effects of novel GPx1-mimetics in diabetic nephropathy
Prof Ranjeny Thomas	The University of Queensland	QLD	Pathological changes associated with chronic RelB activation in type 1 diabetes
Dr Chris Tikellis	Baker IDI Heart and Diabetes Institute	VIC	ACE2 in the vascular complications of type 1 diabetes
Dr Michael Ward	Mater Medical Research Institute	QLD	Mitochondrial dysfunction in diabetic kidney disease
Dr Yuxia Zhang	Walter and Eliza Hall Institute of Medical Research	VIC	Engineering antigen specific regulatory T cells

National Health and Medical Research Council and JDRF co-funded program grants

Prof Anthony d'Apice	St Vincent's Health	VIC	Which transgenic pig will be used for islet transplantation in humans?
A/Prof Shane Grey	Garvan Institute of Medical Research	NSW	Beta cell mass and function in type 1 diabetes and islet transplantation
Prof Ed Stanley	Monash University	VIC	Derivation of pancreatic beta cells from embryonic stem cells
Prof Joseph Trapani	University of Melbourne	VIC	Cell death pathways and type 1 diabetes

Australian Type 1 Diabetes Clinical Research Network

Principal Investigator	Project
A/Prof Maria Craig	The Australasian Diabetes Data Network
A/Prof Alicia Jenkins	Reducing with Metformin Vascular Adverse Lesions in type 1 diabetes (REMOVAL)
Prof Tim Jones	Hypoglycaemia Prevention with Predictive Suspension of Insulin Delivery
Prof Anand Hardikar	A clinical study for validating beta cell death in type 1 diabetes
Prof Lin Perry	Telehealth to support insulin pump users in regional and rural Australia
Dr Michele O'Connell	Exploring the acute impact of hypo- & hyperglycaemia on brain function in Type 1 diabetes
Prof Shane Grey	Islet epigenetic programming and reprogramming during transplantation
Prof Eccosse Lamoureux	Retinal vascular function during hyperglycaemia and the role of vitamin C
Prof Jenny Gunton	Machine-Intelligent Artificial Pancreas System
Dr Melinda Coughlan	Elucidating mitochondrial defects in human diabetic nephropathy
Prof Stephen Twigg	Type 1 Diabetes and Exercise RCT of an On-Line Educational Tool
A/Prof Maria Craig, Prof Tim Jones, Prof Ranjeny Thomas, Prof Grant Morahan	Collaborative Biospecimen Data Linkage Project

The Clinical Research Network

In 2012-13, the Australian Type 1 Diabetes Clinical Research Network (CRN) consolidated a strong foundation of support initiatives, and strategically funded translational research programs that will deliver research from the laboratory to life-changing therapies for people with type 1 diabetes.



**Australian Type 1 Diabetes
Clinical Research Network**

Laying a solid foundation of a strong collaborative network

The CRN was established by JDRF in 2010 to address a gap in the research pipeline – the necessary investment into translational research. By increasing the volume and scope of clinical research, the CRN can deliver better therapies and health outcomes to the 122,300 Australians living with type 1 diabetes.

Facilitating collaboration and consultation in the research community

Through activities such as the annual CRN meeting that was attended by over 30 researchers, the Australasian Diabetes Data Network, and a collaborative biobanking study funded by the Pilot and Feasibility Grants, the CRN is creating opportunities for Australia's top researchers to coordinate, collaborate and communicate.

Helping funded projects meet planned outcomes

A new Coordinated Patient Recruitment Scheme worth \$45k was developed and implemented by the CRN in FY2012-13. This includes a dedicated marketing communications plan for promoting the CRN and clinical trials to the Australian type 1 diabetes community.

Increasing Australia's capacity for clinical trials

The CRN awarded over \$700k to 9 Pilot and Feasibility Grants. The introduction of this initiative in FY2012-13 for exploratory research studies is building a solid foundation for large-scale clinical trials in the future.

Cultivating the next generation of talented researchers

The Mentored Clinical Researcher Fellowship supports talented clinician researchers in developing their career in type 1 diabetes research. With two newly awarded Fellowships in FY2012-13, the CRN is actively building a pipeline of the next generation of talent in type 1 diabetes research.



A Young Advocate

Eight-year-old Zachary Wall was diagnosed with both coeliac disease and type 1 diabetes in 2011.

Zac does his blood sugar level tests and insulin injections and says “I would like a cure for type 1 diabetes because I would like to not do this every day. If the Government helped scientists find a cure, it would help a lot of kids”.

To do his part in encouraging Government to fund more type 1 diabetes research, Zac is a JDRF Government Advocate. He met with his local member The Hon Tony Smith MP during the *Promise to Remember Me* campaign, and also met with him at *Kids in the House* to talk about funding for the Australian CRN.

Zac went to the Federal Government's Melbourne Community Cabinet in April 2013 and secured a meeting with then-Treasurer Wayne Swan and then-Prime Minister Julia Gillard.



At this meeting, Zac was told by Wayne Swan that “Advocates from JDRF are so coordinated...you are always everywhere!”

In response, Zac said “That’s because, Treasurer, we never get a day off from type 1 diabetes!”.

Government advocacy is just one way that Zac and the Australian type 1 diabetes community come together to pursue their common purpose.

Community Voices

JDRF Advocates are a powerful voice for the Australian type 1 diabetes community.

JDRF Advocates build strong influential relationships with their local politicians and advocate for research and program funding, and health policy change. As part of the 2012 *Promise to Remember Me* campaign, 250 advocates met with 135 politicians from nearly all federal electorates across the nation to ask for more funding for the Australian Type 1 Diabetes Clinical Research Network (CRN).

During and after the campaign, advocates connected with each other on the JDRF Advocacy Facebook group, sharing media coverage successes, encouragement, and ideas for how to best secure a meeting with an MP.

In the first half of 2013, 26 JDRF advocates took part in three Government Community Cabinet meetings in Perth, Melbourne and Sydney to meet with senior Government Ministers. JDRF advocates were held up by Australian Government as an example of how to run an effective and coordinated advocacy campaign.

They secured several one-on-one meetings with the Prime Minister, Minister for Health, Treasurer and Minister for Research, continuing the community's lobbying for further funding of the CRN.

JDRF advocates secured a
the CRN from the Coalition,
in the official 2013 Liberal

Community Voices in Canberra

Directly following the *Promise to Remember Me* campaign, the JDRF *Kids in the House* event in November 2012 brought 100 JDRF Government Advocates with type 1 diabetes to Canberra to meet with their MPs.

For the first time, JDRF secured a Private Members Motion on the floor of the House of Representatives, with twelve politicians from both major parties promising to remember all Australians with type 1 diabetes.

With 106 meetings reinforcing connections to 130 politicians across political parties, the Australian parliament showed a strong commitment to the type 1 diabetes community.



commitment of \$35m for
with this commitment listed
Party policy platform.

Connecting Communities

Insulin Pump Program

The Australian Type 1 Diabetes Insulin Pump Program (IPP) is funded by the Commonwealth Department of Health and Ageing and administered by JDRF.

It provides much needed support in the form of financial subsidies for insulin pumps for children under 18 whose families meet the means-tested criteria. Over the four and a half years of the program, pump subsidy recipients consistently reported a better quality of life and improved health benefits after starting use of an insulin pump.

In FY 2012-13, JDRF distributed 76 pumps through the IPP, exhausting all available Government funding for the financial year.

JDRF and our advocates continue to work with the Australian Government to secure further ongoing funding for the program and improved access to therapies for people with type 1 diabetes.

"The insulin pump has made a dramatic difference to my son's quality of life, helping to regulate his highs and lows. Thank you JDRF!"


Jenny, mother of a child with type 1 diabetes.

JDRF Online Community

The JDRF online community come together to share stories and experiences of life with type 1 diabetes through our *Path to a Cure* blog and e-newsletter, our Facebook page, and our Twitter network.

With over 40,000 subscribers to our e-newsletter and 10,000 Facebook followers, JDRF connects Australians with type 1 diabetes in a digital environment to discuss the issues facing the type 1 diabetes community today.

Our online community continues to grow with more passionate participants every day who create and contribute content and stories for the community.



Resources Program

The JDRF Resources Program supports Australian families and individuals from the point of diagnosis of type 1 diabetes.

We distribute resources to families and individuals through healthcare professionals, including:

- The *KIDSAC* pack for newly diagnosed children including Rufus or Ruby, the bears with diabetes.
- The *t1d kit* for adolescents and adults, a starter kit for life with type 1 diabetes.
- The *Straight to the Point* book for young adults and adults, written by health care professionals and people living with type 1 diabetes.

Each resource is carefully designed to meet the needs of people with type 1 diabetes, providing them with the information they need.

"Ruby Bear is my daughter's best friend. Because of Ruby, she was able to accept her type 1 diabetes."

Julie, mother of a child with type 1 diabetes.

The JDRF Resources Program is kindly supported by Roche Diabetes Care and Sanofi.

In FY 2012-13 we distributed

729
Straight
to the
Point
books

718
T1D
kits

1144
KIDSAC
packs

To over 516 hospitals and diabetes clinics


Peer Support Program

The JDRF Peer Support Program connects newly diagnosed families and individuals with people who are already living with type 1 diabetes and can provide practical advice on what it means to live with type 1 diabetes from day to day.

In FY 2012-13, our Peer Support volunteers called 1342 newly diagnosed people to offer peer connection. 386 people joined the program, and were supported by and connected to the Australian type 1 diabetes community.

100 JDRF Peer Support volunteers from around Australia work together to let newly diagnosed families and individuals know: **You are not alone. We are here to help.**

The JDRF Peer Support Program is partially supported by Lilly Diabetes.



Funding a Cure



Walk to Cure Diabetes

The 2012 Walk to Cure Diabetes united communities around the country as part of the largest type 1 diabetes fundraising event in Australia. When 40,000 people connected by type 1 diabetes come together, there is a strong sense of community.

Held at 32 locations, the Walk allowed the community to build awareness of type 1 diabetes, raise money for research, and connect with others. In 2012, the Walk to Cure Diabetes raised over \$1.6m for the best and most promising Australian research into type 1 diabetes.

The Walk to Cure Diabetes helps to create a community with a common voice and common desire to cure, treat and prevent type 1 diabetes.

Ride to Cure Diabetes

2013 marked the 10th year of the Ride to Cure Diabetes, an incredible event with unmatched camaraderie and a shared sense of passion and purpose.

In 2013, 325 Riders chose to ride 35km, 80km or 160km through the Barossa Valley over a sunny weekend in January, raising over \$1m for type 1 diabetes research.



The JDRF Spirit Award was renamed the Leanne Chronican Award for Courage, Determination and Spirit in honour of Leanne Chronican, a Foundation Cycling Club member who passed away as a result of the side-effects of type 1 diabetes complications. Team Whyalla was awarded the Day Rider Leanne Chronican Award and Phil Chronican was awarded the Weekend Rider Leanne Chronican Award. Congratulations to Team ANZ who received the award for Highest Corporate Team Fundraising.

Thank you to our long-time supporters Bernie Jones Cycles, Motorola, and the Rotary and Kiwani Clubs of the Barossa Valley.



Gala Balls

Around Australia in May and June over 1000 people came together to support type 1 diabetes research at a night of Tokyo-inspired glamour at the JDRF Gala Balls in Perth, Sydney and Brisbane.

Raising over \$800k in 2013, the events featured exciting fundraising opportunities such as the silent and live auctions, Fund a Cure donations, Wine Wall, Treasure Chest, and raffles.

In 2014, a new JDRF Gala Ball will be held in Melbourne, offering an opportunity for the type 1 diabetes community to unite with JDRF behind a common cause on a fun night out.

Thank you to the JDRF Gala Ball Committees for their dedication and commitment to securing auction items and selling tickets, and to our generous sponsors and supporters who donated items for the auctions.

Team Cure Diabetes

The dedication to the JDRF mission that characterises the type 1 diabetes community also motivates people to create opportunities to raise money for research in their own time, using their own resources and big ideas. These people join Team Cure Diabetes, a group of passionate people who are seeking a cure for type 1 diabetes.

Team Cure Diabetes raised over \$1.1m in FY 2012-13 with over 400 innovative fundraisers from around Australia taking part in a wide variety of fundraising activities.

From participating in mass fitness events to innovative individual fundraisers, the members of Team Cure Diabetes came together as a powerful group with a big impact on type 1 diabetes research.



Jelly Baby Month

Over 1000 passionate people get involved with raising funds for type 1 diabetes each May for Jelly Baby Month. The inaugural Jelly Baby Breakfast program in 2013 was a great success with over 50 community events held across the country.



With media coverage on ABC, Sunrise and commercial radio spots, millions of Australians got to learn more about type 1 diabetes and contribute to the nearly \$900k raised through the campaign.

With thanks to the generous support of Woolworths and Safeway supermarkets, Amcal and Amcal Max Pharmacies, and our distribution partner Toll IPEC, Jelly Baby Month reached communities all around Australia.

Jump to Cure Diabetes

The Jump to Cure Diabetes is a life-changing event that starts with passionate people who want to challenge type 1 diabetes.

Each jumper raised over \$1000 each for JDRF and type 1 diabetes research, and then joined other daring skydivers in an exhilarating jump out of a plane.

In 2013, 255 people from around Australia came together over ten days at eight sites around the country, raising over \$450k for life-changing type 1 diabetes research.



A common cause

Passionate people give to JDRF in a variety of ways.

The type 1 diabetes community connect in person at fundraising events, combining efforts and raising significant amounts of money for type 1 diabetes research.

People give generous financial contributions through regular monthly donations, individual donations, payroll giving, and leaving bequests to JDRF in their will.

Businesses and organisations donate their time, expertise, resources, and money through partnerships, pro-bono and in-kind support.

These contributions combined help JDRF to fund a brighter future free of type 1 diabetes for everyone who is currently living with type 1 diabetes and those who may develop the disease in the future.

With this support, JDRF is progressing research towards curing, treating and preventing type 1 diabetes.



Craig Alexander and the Kilanda Fireworks

My family has been living with type 1 diabetes for 18 years, since my son Dominic was diagnosed at 3.

The diagnosis was completely out of the blue with no family history of type 1 diabetes at all. When I started concentrating on raising funds for research, I decided that JDRF was the most relevant charity for my family. At that time, we were waking up at 2am in the morning to test Dominic's levels, and we wanted to support an organisation who could deliver a future where we didn't have to do that anymore.

I started organising an annual fireworks night at Kilanda, our family property, near Wagga Wagga in New South Wales, raising \$1000 in our first year. Over time, this night has grown to the point where it is one of the biggest shows in the area, raising around \$14k every year and attracting 400 to 500 people to the event.



We decided that 2013 was going to be the last year of the Kilanda Fireworks, but with lots of other ideas for fundraisers, our involvement with JDRF will be ongoing.

Ultimately, I hope that our fundraising efforts will help to find an end to type 1 diabetes. In the meantime, better treatments that can maintain a healthy happy life after diagnosis can help Dominic and other people living with type 1 diabetes.

Craig Alexander

JDRF fundraiser and father of a son with type 1 diabetes

Recognising achievements of health care professionals

Diabetes Educators are very important people in the lives of Australians with type 1 diabetes. They work hard to improve the lives of their patients, ensuring that each individual has a special diabetes management plan that suits their lifestyle.

The peer and patient nominated JDRF Diabetes Educator of the Year program is designed to recognise and thank Diabetes Educators for their exceptional contribution and dedication to the lives of their type 1 diabetes patients.

With the support of Abbott Diabetes Care, the program aims to reward the passion, dedication, excellence and experience that Diabetes Educators share with the community. From a total of 120 nominations, four outstanding Diabetes Educators were awarded a Diabetes Educator of the Year Award for 2012.

Category	Winner
Excellence and Innovation	Annette Keid, Caboolture Diabetes Service
Impact and Relationships	Marion Starosta, Royal Hobart Hospital
Lifetime Achievement	Cheryl Steele, Footscray and Sunshine Hospitals
People's Choice	Charmaine De Bliek, Ringwood Specialist Centre

Recognising achievements of passionate volunteers

JDRF Australia was founded more than thirty years ago by a group of passionate parents who came together to campaign for a cure for type 1 diabetes. Today, our volunteers continue to display their passion, drive and commitment as a united community as they work with JDRF in different ways to find a cure for type 1 diabetes.

The JDRF Volunteer of the Year Awards recognise and thank the people who have freely given their time and talents to help develop a future free of type 1 diabetes. In FY 2012-13, we recognised inspiring fundraisers, young advocates, committee members, peer support volunteers, and event and office volunteers.

The below volunteers were recognised by the Award Review Panel for their particular contributions:

National Volunteer of the Year – Greg Donovan

National Young Volunteer of the Year – Shannon Doody

State Volunteer of the Year (Impact) – Mel Eveille (ACT), Fahina Talanoa (NSW), Brenda Storey (QLD), Eliza Bartlett (SA), Kylie Ettershank (TAS), Julie Merrett (VIC), Janet Woodall (WA)

State Volunteer of the Year (Contribution) – Helene Bruncker (NSW), Brenda Storey (QLD), Ride to Cure Diabetes Committee (SA), Jenny Simonds (WA), Rina Lewis (WA)

State Young Volunteer of the Year – Becky Holt (NSW), Carrie Forbes (QLD), Jordan Cirocco (SA), Joshua, Christian and Noah Merrett (VIC), Fraser Rose (WA)

Greg Donovan and the Big Red Run

As a professional, well-recognised and long-standing global charity, JDRF was the charity I wanted to support.

My son Steven was diagnosed with type 1 diabetes and coeliac disease in 2008 at the age of 14. The months after diagnosis were difficult. There was so much to learn and we didn't even understand the difference between type 1 diabetes and type 2 diabetes.

It wasn't until the end of 2011 that I started thinking about what I could do to help raise funds and awareness for type 1 diabetes.

I established the Born to Run Foundation and the Big Red Run event not only to fundraise for type 1 diabetes research, but also to set a positive sporting example for all young people with type 1 diabetes.

One of my Born to Run teammates has type 1 diabetes, and has managed to complete numerous ultra-marathons with the Foundation. Steven also completed the Big Red Run with me – a huge achievement. They help to demonstrate that type 1 diabetes doesn't get in the way of physical activity, and that people with type 1 diabetes can still do anything they want.



I have big plans for future fundraising activities through the Born to Run Foundation, with a Burke and Wills Trek and Sydney Trailfest being the next events, and Big Red Run again in July 2014.

Every dollar counts towards type 1 diabetes research, and I know that we are making a difference.

Greg Donovan

JDRF National Volunteer of the Year

Our Corporate Supporters

Macquarie Group and the Macquarie Group Foundation

Macquarie Group has been a supporter of JDRF since 2002. In this time the Macquarie Group Foundation and Macquarie Group employees have played a leadership role in fundraising for medical research to find a cure for type 1 diabetes.

Starting with \$10k in support of the Jelly Baby Ball in Sydney, the support provided now encompasses multiple fundraising and partnership activities here in Australia as well as in the UK, Canada and USA. In excess of \$2m in total funds has been raised from employee fundraising and matching gifts from the Macquarie Group Foundation for the Walk to Cure Diabetes, Jelly Baby Ball events, Spin to Cure Diabetes, Ride to Cure Diabetes and JDRF Global Cycle Challenge.

In 2008, the Macquarie Group Foundation committed \$2m to JDRF over 4 years to support research innovation in Australia through a formal partnership. In 2013, this has been expanded into the Macquarie Group Foundation Global Diabetes Research Innovation Partnership which will see further contributions invested into T1D research globally across the JDRF network.

In addition, Macquarie staff play a role in the governance and leadership of JDRF nationally and at a state level.

The Macquarie Group and the Macquarie Group Foundation was also awarded the JDRF International Corporate Partner of the Year Award in 2013.

City Beach

Since 2005, over \$1m has been donated to JDRF by City Beach Australia. These funds have been raised through the sale of wristbands in their network of retail stores, and are a major contributor to JDRF revenue and wider awareness of type 1 diabetes in the general public. We thank them for their ongoing dedication to our cause.

DNS IT

As an international IT services provider, DNS IT generously supports JDRF through the provision of desktop support, network development and the planning process for a long-term IT strategy for all JDRF state offices. The personal attention and dedication of Jonathan Salmon, CEO and Managing Director, has been integral to the growth and success of the partnership.

Toll IPEC

The support of Toll IPEC is one of the key reasons for the continued success of JDRF's Jelly Baby Month. Their important contribution of delivering fundraising merchandise throughout Australia to retail partners and volunteers ensures that more of the revenue from Jelly Baby Month goes where it is needed – the support of research to cure type 1 diabetes.



QBD The Bookstore

QBD support JDRF through the sale of envirobags in their retail stores. 100% of the proceeds from each bag sold are directly given to JDRF, and we thank QBD for their dedication and commitment to supporting Australians with type 1 diabetes.

McKinsey & Company

McKinsey & Company has been supporting JDRF through pro-bono management consulting services. They have worked with JDRF staff in developing strong management skills and a robust and strategic plan for the future. Their contribution has helped JDRF become a stronger and more efficient organisation

Commonwealth Bank of Australia and ISIS

The Commonwealth Bank of Australia in conjunction with ISIS has generously supported JDRF through the planning and execution of renovations to the JDRF Sydney office. Their joint contribution of time, personnel and resources has assisted JDRF and improved the working environment for JDRF staff.

Herbert Smith Freehills

Herbert Smith Freehills supports JDRF through the provision of legal advice and expertise. Their valuable input helps JDRF in continuing innovation and creating better business outcomes for the type 1 diabetes community.

King & Wood Malleons

King & Wood Malleons is one of JDRF's trusted legal advisory firms, offering important legal advice on a variety of business situations. Their contribution helps JDRF in managing the environments in which we work, enhancing the quality of our work in funding medical research.

Woolworths

Woolworths Supermarkets have been strong supporters of the successful JDRF Jelly Baby campaign since 2003. Their generosity and efforts in selling JDRF Jelly Baby merchandise through their stores around the country raise \$500k annually for Australian type 1 diabetes research.

AMCAL

Amcal and Amcal Max, and their parent company Sigma Pharmaceuticals, have been valued partners of Jelly Baby Month since 2003. We thank them for their support, with tens of thousands of products sold through Amcal over the years, raising over \$300k for type 1 diabetes research.



Our Industry Partners

Roche Diabetes Care

Roche Diabetes Care has been a supporter of JDRF's programs for more than six years through their ongoing support of JDRF's fundraising events and *KIDSAC* program. Their Accu-Chek products offer people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management spanning from lancing and blood glucose monitoring through information management to insulin delivery.

Medtronic Australasia

Medtronic Australasia has been a strong supporter of JDRF's government and media engagement activities. With the help of our Government Advocates and with support from Medtronic, JDRF regularly engages government to promote type 1 diabetes research. Medtronic is also a supporter of JDRF's T1D Truth Awards, which recognises excellence in writing about the life and science of type 1 diabetes.

Sanofi

Sanofi has supported JDRF through regular participation in JDRF's events and continuous support of the *KIDSAC* and *t1d kit* information packs. These resources provide assistance to diabetes educators. A recent review of health care professionals reiterated the value of these packs in helping them educate and inform the newly diagnosed type 1 diabetes community.

Lilly Diabetes

Lilly Diabetes has joined forces with JDRF in a collaborative partnership with the shared goal of extending the reach of the Peer Support Program to more people living with type 1 diabetes in Australia. The Peer Support Program addresses a need children living with type 1 diabetes and their caregivers have to connect with other families who also live with the condition every day. Lilly also supports JDRF through fundraising events and staff volunteering.

Abbott Diabetes Care

FreeStyle and Abbott Diabetes Care understands the fantastic work that the health care professionals provide, and recognises them through sponsoring the national JDRF Diabetes Educator Awards. The program awards Diabetes Educators with industry recognition and funds to spend on resources and facilities for their clinic that improve patient care. For 20 years, Abbott Diabetes Care has helped Australians with diabetes live healthy and active lives through technology, support, and education.

Novo Nordisk

Novo Nordisk is dedicated to drive change for people with type 1 diabetes, and has shown this dedication through partnerships with JDRF including support for the JDRF e-newsletter Path to a Cure.



Recognising generous contributors

Major Supporters

Anonymous (5)
Susan Alberti AO
Tessa Alberti
Peter and Rosemary Appleton
James and Kim Auswild
Elizabeth M Avery
Karen Barfoot
Tim and Vanessa Bednall
Gavin and Karen Bird
Bob Bollen
Jeffrey and Karen Browne
Matthew and Nickie Buckley
Dennis Bunnik
Helen Bunning
Paul Brunker
Peter and Wendy Bot
Tom and Suzanne Castles
Malcolm and Kathy Clift
Ian and Wendy Coghill
Phil Chronican
Anthony Cole
Lilla Corvaia
Gary Crabtree
Joanne Crosby and Carey Lyon
Rebecca Davies and Robert Quirk
Bruce Duncan
Roy Edwards
Diane and Ed Federman
Paula Flaherty
David and Narelle Foster
Joan Grant
Sandra Genovese
Amanda Gosney
Richard and Janine Goyder
Catherine Hamber
Kim Harding
Michael Harrison
Jill and Brian Harrisberg
Stephen and Roey Higgs
Rosanna and John Hindmarsh
David and Rosemary Houseman

David Hume
Gil and Di Kerr
David and Joan Keane
Gene Koltasz
Gabrielle Krohn
Alex Lumby
Peter and Jenine McGeorge
Kerry Maddestra
Natasha and Laurence Mandie
Miss Maud
Helen McCombie
Lloyd and Irene McGuire
Nerida McKnight
Bruce and Julie Mills
Lorna and Brian Mellor
Martine Naeve
Marianne and Peter Nestor
Simon Nestor
Colin North
Raymond Pershouse
Peter Pynes
Steven J Richards
Caroline and Philip Rose
Desleigh Rose
Arne Schimmelfeder
Ian C Scott
Jack and Marlene Sheedy
Simon Squire-Wilson
Jillian G Skinner
Peter and Mary Straton
Melinda and Craig Sweeney
Christine Taylor
Alycia Utberg
Celia Waters and David Harvey
William and Yvonne Wavish
William A Webster
Heidi and Craig Welsh
Brian White
Stephen White
Tom and Rebecca Wiley
Ted and Mandy Yencken

Organisations

Abbott Diabetes Care
Abey Family Foundation
Amcal
AMSL (Animas)
AON Leadership & Growth Conference
Australian Diabetes Council
Australian Football League
Benz Industries Pty Ltd
BHP Billiton Mitsubishi Alliance
Born2Run Foundation
Callinan Media
City Beach Australia
Commonwealth Bank of Australia
DNS IT
Greenstone Property Pty Ltd
Herbert Smith Freehills
Home Group WA Pty Ltd
JJ Richards and Sons Pty Ltd
King & Wood Mallesons
Lacetree Pty Ltd
Lilly Diabetes
McKinsey
Medtronic Australasia
Moore Stephens
Nipro Australia Ltd
Novo Nordisk
Pinnacle Hospitality and Travel People
QBD Bookstores
Quest on William, Melbourne
Queensland Government
Roche Diagnostics Australia
Ron Farris Real Estate
Sanofi Australia New Zealand
Specialist Mail Services
Talking Point
Toll Charity Classic

Trusts and Foundations

ABN Foundation
Anonymous (1)
Australian Executor Trustees
Australian Philanthropic Services Foundation
The Baker Foundation
Born To Run Foundation
Count Charitable Foundation
Danii Meads-Barlow Foundation
Emorgo Foundation
Evans Foundation
The G W Vowell Foundation Limited
Hacket Foundation
Helpful Foundation
Macquarie Group Foundation
Maple-Brown Family Charitable Foundation
McCusker Charitable Foundation
Morialta Trust Incorporated
The Pace Foundation
Peta Seymour Foundation
Rees Family Foundation
Snow Foundation Limited
The Trust Company
Wilson HTM Foundation

JDRF Bequestors

Anonymous (8)
Catherine Adams
Edward Ashton
Jane Barron
Muriel Boyer
Kallie Blauhorn
Will C Bonney
Barbara Brown
Carrie Burhop Keller
Cheryl Cartwright
Kirrily Chambers
Elaine Chapman
Phil Chronican

Ian and Wendy Coghill
Chris Cuellar
Rebecca Davies
Paul Davis
Deb Davis
W Epps
Joan Grant
Janice Green
Lyndal Howison
Brian and Kayleen Johnson
Zuhal Kuvan-Mills
Sarah Marshall
Kristen Mason
Helen Maxwell-Wright
Dennis and Pat McDermott
Paula McDonald
Hugh McLelland
Rhonda McLelland
Rory C Moore
Gregory Northey
Gina Pash
Rod Pearse
Stan Platis
Elizabeth A Rayward
Meaghan Read
Audrey Schultz
Jennifer Slogan
Aileen Smith
Harold Smith
Mike Wilson

Top Walk Fundraisers

Walkers of Merrett
Koby's Krew
Hannah's Happy Herd
Fraser Rose
Kiah Aylee
J Walkers
Ashleigh Yarak
Ella's Crusaders
Kiarna Krump
Julia Cirjak

Top Ride Fundraisers

Team ANZ
Team Boral
Western Flyers
Team Macquarie
Team SFG
Webb & Brown-Neaves
Team Westpac
ACT Sprocket Men and Women
Team Noah
Groundwork Plus

Top Team Cure Diabetes Fundraisers & Events

North Queensland Gala Ball
Craig Pinn
Royal Perth Golf Club
Brenda Storey
Color Run Perth
Sophie Curra
Eliza Bartlett
Wynnum Golf Day
Cathryn Urquhart
IPG Canberra
Beke and Penny Holt
Craig Alexander
Perth to Busso Cycle Group
Leckie's Golf Day

JDRF makes every effort to ensure the accuracy of these lists. If you have any questions, please contact us on info@jdrf.org.au.

Corporate Governance

JDRF and its Board are committed to achieving and demonstrating high standards of corporate governance.

JDRF's corporate governance framework was developed with reference to the best practice recommendations released by the Australian Securities Exchange Corporate Governance Council in 2007 and updated in 2010. The Board continues to review the framework and practices to ensure they meet the interests of members.

Organisational Strategy

Our organisational strategy for FY 2013-14 recognises three focus areas through which JDRF can deliver our mission of finding a cure for type 1 diabetes and its complications through the support of research.

- Accelerating research and health outcomes
- Generating increased revenue and resources
- Being an exceptional organisation.

These three focus areas allow us to create a strong resourceful, and effective organisation working for the Australian type 1 diabetes community.

Funding for mission

JDRF Australia is committed to ensuring that fundraising activities are carried out in an ethical manner. Fundraising activities are conducted by JDRF and take place without the payment of success fee-based commission or any similar arrangements to external agencies.

We are proud to partner with members of the type 1 diabetes community who take the initiative to run their own fundraising campaigns, which we support via transparent online fundraising tools. Our online fundraising channels all use secure payment gateways and have nominal transaction fees.

One global voice

JDRF Australia is an affiliate of JDRF International based in the USA, along with similar bodies in Canada, the UK, Israel, Denmark, Germany and the Netherlands.

Funds raised by JDRF Australia are directed into the most promising type 1 diabetes research projects and pathways within Australia. Due to the strength of the Australian research environment, Australian researchers attract one of the highest per capita allocation of competitive research investment by JDRF International.

Finances

JDRF is a registered charitable organisation. Its principal activities are to raise funds and conduct advocacy to support research to find a cure for, treat and prevent type 1 diabetes. JDRF also raises awareness of the seriousness of type 1 diabetes, and offers practical support to people with type 1 diabetes and their families.

JDRF financial activities are geared towards achieving this goal with minimal expenditure on company administration and financial risk.

The role of the Finance & Audit Committee is to provide oversight and advice on the financial activities of the organisation. It is responsible for working with the CEO and senior managers on developing and tracking budgets, monitoring forecasts, and reviewing management accounts and statutory accounts. Independent members and JDRF Directors sit on the Finance & Audit Committee, and reflect a diverse range of backgrounds and experience.

Members

Trevor Allen*	Non-Executive Director, Peet Ltd
Stephen Higgs*	Director, Peet Ltd
Fiona Hindmarsh	Client Development, Family Office and Wealth Services, The Myer Family Company Limited
Boris Musa	Managing Director & CEO, Mainstream Aquaculture Pty Ltd
Colin North (until May 2013)	Senior Consultant and Past Owner and Managing Director, Major Furnace Australia Pty Ltd
Peter Whyntie	Director & Principal Consultant, Peter Whyntie Associates Pty Limited
Peter Wilson*	Director, Mainstream Aquaculture Pty Ltd

*Denotes also a director of JDRF

Risk assessment and management

The Board is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems. Company policies are designed to ensure strategic, operational, legal, reputation and financial risks are identified, assessed, effectively and efficiently managed and monitored to enable achievement of the organisation's objectives.

Considerable importance is placed on maintaining a sufficiently strong control environment. There is an organisational structure with clearly drawn lines of accountability and delegations of authority.

In order to strengthen JDRF's position with respect to Risk Management (including Workplace Health and Safety), a full Risk Management Strategy incorporating a Risk Management Policy was adopted by Directors. Subsequent to that approval the development of a risk management plan has commenced, including the appointment of a Risk Manager and the creation of a formal Risk Management Committee with associated Charter.

Board of Directors

The Board operates in accordance with the broad principles set out in its Constitution as adopted by the company on 8 April 2000. A Board Charter has been approved by the directors and aids in guiding the operation and activities of the Board.

Directors Qualifications and Special Responsibilities	Experience
Chairman Stephen Higgs, BEc Member of the Finance & Audit Committee Member of the JDRF Advisory Board Member of the Ad Hoc Lay Review Panel after 3 years on the full committee. Member of the Nominations & Governance Committee	Director, Peet Ltd Chairman, Glycemic Index Ltd. Past Chairman, Orlando Wines. Austoft Pty, Jasco Pty Ltd, NPL Ltd, Leigh Mardon Pty Ltd, Rural Press Ltd, IPAC Securities Ltd, So Natural Foods Ltd, Primary Health Care Ltd and UBS Warburg Father of a son with type 1 diabetes
Vice-Chair Paul Heath Chair of the Remuneration Committee Member of the Nominations & Governance Committee (appointed on 30 November 2012)	Board Director, Beyond Empathy Member, Endowment Investment Committee of the Benevolent Society Former CEO, JB Were Goldman Sachs Father of a daughter with type 1 diabetes
Vice-Chair Natasha Mandie, B Comm (Hons), LLB (Hons), GAICD Member of the Remuneration Committee Member of the Nominations & Governance Committee (appointed on 30 November 2012)	Managing Director, Mandie Consulting Boutique Corporate Advisor Non-executive Director of a number of private technology companies Former Director, Corporate Advisory Solutions, Credit Suisse Has type 1 diabetes
Treasurer Trevor Allen, BCom (Hons), CA, FF,MAICD Chair of the Finance & Audit Committee	Non-Executive Director, Freedom Foods Group Limited Non-Executive Director, Peet Ltd Former national Head of Mergers and Acquisitions and Partner at KPMG Former Executive Director, SBC Warburg Has a sister with type 1 diabetes
Honorary President Susan Alberti, AO, MAICD International Patron JDRFI Member of JDRFI Board of Chancellors Former Member of Major Donor Committee JDRFI Retired Member of Board of Directors JDRFI Retired Chairman of JDRFI Development Committee	Managing Director, Dansu Group Director, Western Bulldogs Football Club Co-Chair, Western Bulldogs Forever Foundation Ltd Director, GoldAge Pty Ltd Foundation Chair, St Vincent's Institute of Medical Research Director, St Vincent's Institute of Medical Research Member of the Advisory Group for the Australian Community Centre for Diabetes Retired Director, Click Foundation (Epilepsy) Director, Victoria University Foundation Member of the Australia Day Committee (Victoria) Chair of the Susan Alberti Medical Research Foundation Director, Western Health Foundation

Directors Qualifications and Special Responsibilities	Experience
Chief Executive Officer Company Secretary Mike Wilson , GAICD, BSc, BEc (Hons)	Director, Glycemic Index Foundation Director, Somark Innovations CEO, JDRF Australia since 2004
Robert Antulov , BE, MBA, MIEAust, MAICD	Corporate Advisor and Company Director Director, Medianext Pty Ltd Director, Sydney Film Festival Director of Choice (Australian Consumers Association) Former Director of Strategy, Fairfax Media Ltd Father of a son with type 1 diabetes
Rebecca Davies , LLB (Hons), BEc, FAICD Member of the Board of JDRFI Chair of the JDRFI International Affairs Committee Member of the JDRFI Research Committee Member of the JDRF Advisory Board Member of the Nominations & Governance Committee (resigned on 30 November 2012)	Company Director Former Partner and board member of a major national law firm Formerly Chair of MLC Nominees Member of the Research Committee of the National Health and Medical Research Council
Stuart Green , B.A. (Hons), MBA, FCA, ACMT	Executive Director, Macquarie Group Ltd Head of Corporate Communications and Investor Relations, Macquarie Group Ltd
Ross Kennan , FIEA, FAICD, MRACI, BSc., Grad Dip Ind Eng., Grad Mgmt IMD (Switzerland) Member of the Remuneration Committee Member of the Nominations & Governance Committee	Chairman, Hindmarsh Old Company Ltd. Former Chairman, Dadanco Pty Ltd. Former Global SBU Vice-President, Honeywell Inc. Former Chairman, Neptune Marine Services Ltd.
Kristen Mason , MBA, BA Chair of the NSW Ball Committee	Senior Manager, Travel Partner Network JAPA, American Express Former Director, Foundation – Kambala Mother of a daughter with type 1 diabetes
Helen McCombie Member of the NSW Corporate Committee	Partner, Citadel Formerly reporter on Channel 9's Business Sunday program
Timothy Morphy , BA, LLB, Grad. Dip. Legal Prac., MBA	CEO, MedHealth Group including its wholly owned subsidiaries MLCOA and NextHealth Former Managing Director, Healthways Australia Pty Ltd.
Jonathan Salmon , MAICD (appointed 30 November 2012)	CEO, DNS IT and Hosted IT Director, Unlisted Marketplace Father of a son with type 1 diabetes

Board of Directors cont.

Directors Qualifications and Special Responsibilities	Experience
Mark van Dyck , BA (Hons), GAICD Member of JDRF Advisory Board Member of the NSW Corporate Committee Member of the Remuneration Committee	Managing Director, Compass Group Australia Former COO of LG Electronics Former Managing Director, Coca-Cola Australia Former Managing Director, Coca-Cola Ireland Board member of GI Foundation Member, NSW Council for Reach Foundation Father of a daughter with type 1 diabetes
Michael L. White , BA, MBA Member JDRFI Board of Chancellors	President and owner, RBW Companies Chair, JDRF Strategic Alliance Committee Member, JDRF Research Executive Committee Father of a son with Type 1 diabetes
Peter Wilson , Dip. Chem. BEc Member of JDRFI Board of Chancellors Member of JDRFI Finance Committee (former Chairman) Member of Finance & Audit Committee Member of the Nominations & Governance Committee (resigned on 30 November 2012)	Director, Mainstream Aquaculture Pty Ltd Former Managing Director and Chief Executive Officer, Spotless Group Limited Former Director, Spotless Director, Taylors Group Limited (a New Zealand company) Retired member, JDRFI Board of Directors Member, International Development Committee JDRFI (former Chairman) Former President, Long Island, New York, Chapter of JDRF Managing Director, PAGA Consulting Pty. Ltd. Director Stanhope Eco Trade Pty. Ltd. Father of a daughter with type 1 diabetes

Advisory Board

Some of Australia's most well-respected leaders of business and science are on the JDRF Advisory Board, donating their skills and expertise to ensure that JDRF continues to be a top-performing organisation. We thank the following people for their involvement.

Co-chairs

Richard Goyder	CEO & Managing Director, Wesfarmers
Ralph Norris	Ex-CEO, Commonwealth Bank

Members

Matthew Grounds	CEO, UBS Australia
Nicholas Moore	CEO, Macquarie Group
Peter Mason	Chairman, AMP
Professor Ian Frazer	Director, Diamantina Institute, University of Queensland
Ian Narev	CEO, Commonwealth Bank
Phil Chronican	CEO, ANZ Bank (Australia)
Jeff Browne	Ex-Managing Director, Nine Network Australia
Sean Larkin	Managing Director, HCF
Paul Heath	Ex-CEO, JB Were Goldman Sachs
Tim Bednall	Partner and Ex-Chairman, King & Wood Mallesons
Andy Penn	CFO, Telstra
Brendan Riley	COO, Telstra
Howard McDonald	Chairman, Rodd & Gunn
Bill Wavish	Principal, Wavish Associates Investments
Rod Pearse	Ex-CEO and Managing Director, Boral
Christopher Corrigan	Former Managing Director, Patrick Corporation
Fiona Packman	Managing Partner, Egon Zehnder
Rebecca Davies	Ex-Partner and Board Member, Freehills
Peter Wilson	Ex-CEO, Spotless Group
Mike Wilson	CEO & Managing Director, JDRF
Steve Higgs	Chairman, JDRF
Mark van Dyck	Managing Director, Compass Group Australia

Senior Managers

Chief Executive Officer	Mike Wilson, BSc, BEc (Hons), GAICD
Chief Operating Officer	Angela McKay, BBus
Head of Development	James Clampett, BEc
Head of Research Development	Dr Dorota Pawlak, MSc, PhD
Government Relations Manager	Suzanne Culph, BA (Hons), MA (from February 2013)
National Manager – Marketing	Lyndal Howison, BBus (from April 2013)
Head of Government Relations	Tanya Stoianoff, B Agr.Ec, MPS (until February 2013)
National Philanthropic Giving Manager	Carrie Burhop Keller, BSc, MBA (until July 2013)
Head of Marketing	Carl Ireland, BBus (Mktg), Grad.Dip (Mktg) (Until August 2012)



Left to right: James Clampett, Lyndal Howison, Mike Wilson, Dr Dorota Pawlak, Angela McKay, Suzanne Culph

Advisory Panels

Professional Advisory Panel

Australian scientists are respected globally for their innovation and results. Our Professional Advisory Panel helps ensure that JDRF funding is directed towards high quality projects with the greatest potential for growth of scientific knowledge.

Professor Phillip O'Connell (Chair)	Westmead Hospital
Associate Professor Trevor Biden	Garvan Institute of Medical Research
Dr Tom Brodnicki	St. Vincent's Institute of Medical Research
Associate Professor Josephine Forbes	Mater Medical Research Institute
Associate Professor Jenny Gunton	Garvan Institute of Medical Research
Professor Timothy Jones	School of Paediatrics and Child Health, University of Western Australia
Dr Cecile King	Garvan Institute of Medical Research
Dr Stuart Mannering	St. Vincent's Institute of Medical Research
Professor Ranjeny Thomas	University of Queensland's Diamantina Institute

Lay Review Panel

People with a personal connection to type 1 diabetes have a deep understanding of what it means to live with it day-to-day. Their input helps us to ensure that key JDRF funding is directed towards projects with the greatest potential to create a better life for people with type 1 diabetes.

Christine Garberg (Chair)	Parent of a child with type 1 diabetes
Gerard Cudmore	Relative of a person with type 1 diabetes
Stephen Higgs	Parent of a child with type 1 diabetes
Ed Davis	Parent of a child with type 1 diabetes
John Males	Parent of a child with type 1 diabetes
Dianne Kerr	Parent of a child with type 1 diabetes
Tim Porter	Has type 1 diabetes
Natasha Mandie	Has type 1 diabetes
Jo Crosby	Parent of a child with type 1 diabetes
Jan Walker	Parent of a child with type 1 diabetes
Trevor Stuart	Has type 1 diabetes

Allied Health and Nursing Professionals Advisory Panel

Allied health and nursing professionals are part of the health management team for people with type 1 diabetes and include nurses, social workers, podiatrists, and eye specialists. Their involvement ensures that we have the most complete idea of what could be beneficial for the broader health of people with type 1 diabetes.

Dr Jane Overland (Chair)	Royal Prince Alfred Hospital
Deborah Foote	Royal Prince Alfred Hospital
Erica Wright	Diabetes Service ACT Community Care

JDRF Australia financial report

Statement of comprehensive income for year ended 30 June 2013

	2013 \$	2012 \$
Revenue from continuing operations		
Fundraising & other revenue	9,824,132	9,173,089
Government grants	1,357,830	1,581,643
Total revenue from continuing operations	11,181,962	10,754,732
Revenue from shares		
Employee benefits expenses	(2,643,896)	(2,496,797)
Fundraising campaign expenses	(751,704)	(781,599)
Communications & technology expenses*	(233,739)	(195,831)
Advertising, promotion and printing expenses	(193,875)	(158,546)
Venue expenses	(597,323)	(625,631)
Other expenses	(694,446)	(861,618)
Total operating expenditure	(5,114,983)	(5,120,022)
Surplus from continuing operations	6,066,979	5,634,710
Research, pump and travel grants	(5,482,890)	(5,844,319)
Education and support	(317,447)	(154,024)
Surplus / (deficit) before tax	266,642	(363,633)
Income tax expense	-	-
Surplus / (deficit) from continuing operations	266,642	(363,633)
Other comprehensive income		
Other comprehensive income/(expense) for the period, net of tax	-	-
Total comprehensive income/(expense) for the period	266,642	(363,633)

* 2013 - this includes \$75,000 in-kind technology support (2012 - \$128,000) of non-cash expenditure items, with a matching amount recorded as non-cash revenue.

JDRF Australia financial report cont.

Statement of financial position as at 30 June 2012

	2013 \$	2012 \$
ASSETS		
Current assets		
Cash and cash equivalents	7,669,976	8,180,170
Trade and other receivables	827,254	843,502
Inventories	154,160	145,620
Total current assets	8,651,390	9,169,292
Non-current assets		
Plant and equipment	118,013	135,653
Intangibles	9,160	5,467
Total non-current assets	127,173	141,120
Total assets	8,778,563	9,310,412
LIABILITIES		
Current liabilities		
Trade and other payables	3,320,212	2,306,759
Provision for long service leave	37,890	35,047
Total current liabilities	3,358,102	2,341,805
Non-current liabilities		
Government revenue received in advance	1,203,680	3,022,575
Provision for long service leave	87,123	83,016
Total non-current liabilities	1,290,803	3,105,591
Total liabilities	4,648,905	5,447,396
Net Assets	4,129,658	3,863,016
EQUITY		
Retained surplus	4,129,658	3,863,016
Total equity	4,129,658	3,863,016

JDRF Australia financial report cont.

Statement of cash flows for year ended 30 June 2013

	2013 \$	2012 \$
Cash flows from operating activities		
Receipts from fundraising activities	9,358,147	8,519,006
Government grants received (Insulin Pump Program)	526,000	802,000
Interest received	409,826	451,925
Payments for operating activities	(4,818,968)	(6,297,254)
Grants and travel awards paid	(5,901,434)	(4,417,783)
Net cash inflow / (outflow) from operating activities	(426,429)	(942,106)
Cash flows from investing activities		
Payments for plant, equipment & software	(83,765)	(14,606)
Net cash inflow/(outflow) from investing activities	(83,765)	(14,606)
Net decrease in cash and cash equivalents	(510,194)	(956,712)
Cash and cash equivalents at the beginning of the financial year	8,180,170	9,136,882
Cash and cash equivalents at the end of the financial year	7,669,976	8,180,170

Statement of changes in equity for year ended 30 June 2013

	2013 \$	2012 \$
Retained surplus at the beginning of the financial year	3,863,016	4,226,649
Net surplus/(deficit) attributable to members of the company	266,642	(363,633)
Retained surplus at the end of the financial year	4,129,658	3,863,016

Contact JD RF

Phone: 1300 363 126
Email: info@jdrf.org.au
Website: www.jdrf.org.au
Facebook: www.fb.me/jdrfoz
Twitter: www.twitter.com/JDRFaus

Our Offices

Australian Capital Territory

16 Thesiger Court
Deakin ACT 2600

New South Wales

Level 4, 80 Chandos Street
St Leonards NSW 2065

Queensland

Level 5, Wickham House
155-157 Wickham Terrace
Spring Hill QLD 4000

South Australia

Unit 3, 497 Marion Road
South Plympton SA 5038

Victoria

Whitten Oval
417 Barkly Street
Footscray West VIC 3012

Western Australia

Unit 3, 181 Main Street
Osborne Park WA 6017

